A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L

West Japan Oncology Group

Research output: Contribution to journalArticle

39 Citations (Scopus)


In this largest phase II trial with advanced thymic carcinoma (TC), carboplatin and paclitaxel (CbP) showed promising efficacy in advanced TC when compared with anthracycline-based chemotherapy, which is the current standard treatment of TC. Our results established that CbP, one of the standard treatments for non-small-cell lung cancer, might be an option as a chemotherapy regimen for TC.

Original languageEnglish
Pages (from-to)363-368
Number of pages6
JournalAnnals of Oncology
Issue number2
Publication statusPublished - Feb 1 2015


All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this